16 results about "Akt inhibitor" patented technology

Disclosed herein are methods for increasing sensitivity of a cancer cell to alternating electric fields by administering an AKT inhibitor, a mammalian target of rapamycin (mTOR) inhibitor, a Phosphatidylinositol 3-Kinase (PI3K) inhibitor, and / or a Glycogen synthase kinase 3β (GSK3β) inhibitor. Disclosed are methods of increasing treatment efficacy comprising applying alternating electric fields to a target site of the subject for a period of time, the alternating electric fields having a frequency and field strength, wherein the target site comprises one or more cancer cells, and administering a therapeutically effective amount of one or more of an mTOR inhibitor, AKT inhibitor, PI3K inhibitor, or GSK3β inhibitor to the subject. Disclosed are methods of reducing viability of cancer cells using alternating electric fields for a period of time, the alternating electric fields having a frequency and field strength in combination with either an mTOR inhibitor, AKT inhibitor, PI3K inhibitor, or GSK3β inhibitor and / or a composition or compound that increases cyclin D1. Disclosed are methods of increasing apoptosis of a cancer cell comprising exposing the cancer cell to alternating electric fields for a period of time, the alternating electric fields having a frequency and field strength; and exposing the cancer cell to a PI3K inhibitor.

Therapeutic methods and pharmaceutical compositions for treating a myeloproliferative neoplasm (MPN), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis, are described. In certain embodiments, the invention includes therapeutic methods of treating a MPN using a combination of a compound of Formula (I) or Formula (II) with a therapeutic agent selected from the group consisting of a JAK inhibitor, an IDH inhibitor, a PD-1 inhibitor, a PD-L1 inhibitor, a PD-L2 inhibitor, an interferon, a PI3K inhibitor, an AKT inhibitor, an mTOR inhibitor, a nucleoside analog, and combinations thereof.

Therapeutic combinations of an AKT inhibitor and a BCL-2 inhibitor; an AKT inhibitor and a glucocorticoid; and an AKT inhibitor, a BCL-2 inhibitor and a glucocorticoid are described. The combinations can be useful in the treatment of acute lymphoblastic leukemia (ALL).

A unit dosage composition of an AKT inhibitor, and in particular, relates to a pharmaceutical composition in unit dosage form includes a compound of formula I-0 or a pharmaceutically acceptable salt thereof, wherein the mass of the compound I-0 or the pharmaceutically acceptable salt thereof is 5 mg to 400 mg calculated as free base.

This invention discloses the use of AKT inhibitors in the manufacture of drugs for the prevention or treatment of breast cancer. In particular, it provides the combination of an AKT inhibitor and fulvestrant in the manufacture of drugs for the prevention or treatment of breast cancer. The combination of an AKT inhibitor and fulvestrant can effectively inhibit the proliferation and colonization of breast cancer cells. The combination is clearly more effective than monotherapy, exhibits additive or synergistic effects, has lower toxicity and side effects to normal cells, is safer, and provides a more effective method for treating breast cancer, thus having significant clinical value.

The invention discloses application of an AKT inhibitor in preparation of a medicine for preventing or treating breast cancer. In particular, the invention provides application of an AKT inhibitor combined with fulvestrant in preparation of medicines for preventing or treating breast cancer. The AKT inhibitor and fulvestrant are combined to effectively inhibit the growth of breast tumor cells and cell clone formation, the combined effect is obviously superior to that of single medication, the additive or synergistic effect is achieved, meanwhile, the toxic and side effects on normal cells are low, the safety is high, a more effective method is provided for treating breast cancer, and the important clinical value is achieved.

This invention relates to the field of biopharmaceutical technology, specifically to the application of miR-140-3p agonists in the preparation of drugs that reverse resistance to PI3K / AKT inhibitors in colorectal cancer. This invention targets and inhibits hnRNPA1-a by miR-140-3p, thereby relieving its abnormal activation of the PI3K / AKT pathway, thus restoring or enhancing the sensitivity of tumor cells to PI3K / AKT inhibitors, achieving a synergistic anti-tumor effect.

The present disclosure provides, among other things, methods for treating an estrogen receptor-mediated disease, disorder, or condition in a subject comprising administering to the subject Compound 1, or a pharmaceutically acceptable salt thereof in combination with an AKT inhibitor, or a pharmaceutically acceptable salt thereof, and related combinations, compositions, uses, and kits.

Bifunctional compounds comprising a GDC-0068 analog that binds AKT isoforms AKT1, 2 and 3 and a degron which represents a moiety that binds an E3 ubiquitin ligase, covalently attached to each other by a linker, pharmaceutical compositions, and methods for treating diseases or conditions mediated by dysfunctional AKT activity.

An AKT inhibitor is provided, which specifically relates to a compound represented by formula I or a pharmaceutically acceptable salt thereof. The present invention further provides a preparation method thereof, and the use thereof in prevention and / or treatment of a disease mediated by AKT protein kinase.

The application belongs to the field of pharmaceutical application and biological medicine technology, and particularly relates to application of AKT inhibitor in preparation of drugs for inducing immune tolerance of islet transplantation. It is found for the first time that AKT inhibitor MK-2206 can effectively induce immune tolerance after islet transplantation, and it is proved through systematic experiments that a short-term intervention scheme of AKT inhibitor MK-2206 can significantly promote long-term survival of islet grafts, and the effect is better than that of traditional immunosuppressants. This belongs to secondary development of known active ingredient drugs, and provides a potential new treatment strategy for clinical induction of transplantation immune tolerance.

The present disclosure relates to methods of treating cancer in a subject, comprising administering to the subject (a) Compound 1, or a pharmaceutically acceptable salt thereof, and (b) an AKT inhibitor. In some embodiments, the AKT inhibitor is capivasertib. In some embodiments, the cancer in the subject is breast cancer or prostate cancer

This invention provides a composition comprising (i) a first agent selected from the group consisting of a BH3 mimetic, an HDAC6 inhibitor, and a TLR-1, -2, and / or -4 inhibitor, and (ii) a second agent selected from the group consisting of a mitochondrial uncoupler, a Bcl-2 inhibitor, a p53 / MDM2 inhibitor, a HSP-90 inhibitor, a PI3K / AKT inhibitor, a BET inhibitor, and a general senolytic. This invention also provides related compositions and formulations, methods, and articles of manufacture.

The invention discloses application of an AKT inhibitor, and the inhibitor is suitable for treating EGFR mutant non-small cell lung cancer or small cell lung cancer, can play a role by inhibiting EGFR kinase activity and down-regulating protein expression, and overcomes the drug resistance problem of existing EGFR targeted drugs. Within a small blood concentration range, cancer cells can be killed.

The invention discloses an estrogen receptor degradation agent and AKT inhibitor combined medicine and application thereof, and belongs to the field of medicine. The combined medicine contains the estrogen receptor degradation agent and the AKT inhibitor which have the same or different specifications and are administered at the same time or respectively, and a pharmaceutically acceptable carrier, can degrade estrogen receptors, inhibit the growth of cancer cells, play a synergistic inhibition role, remarkably improve the effect of treating diseases related to the estrogen receptors, and can be used for treating the diseases related to the estrogen receptors. Good application prospects are realized.

The invention relates to the technical field of medicines, in particular to application of NDV in preparation of an AKT inhibitor synergist. The invention provides an application of NDV (Newcastle Disease Virus) in preparation of an AKT inhibitor synergist. The invention discloses a synergistic effect of the NDV and AKT inhibitor in treatment of hepatocellular carcinoma through in-vivo and in-vitro experiments for the first time. Experimental results show that the NDV can significantly enhance the killing ability of the AKT inhibitor to liver cancer cells, effectively inhibit the growth of tumor cells and induce apoptosis. According to the combined treatment scheme, the limitation that rapid drug resistance is easy to generate when an AKT inhibitor is singly used is overcome, the anti-tumor effect is further enhanced through the immune activation effect of the oncolytic virus, and a novel drug combination strategy with a synergistic mechanism is provided for treatment of hepatocellular carcinoma.